Thromboembolic Events in Patients on Extracorporeal Membrane Oxygenation without Anticoagulation
Open Access
- 1 November 2010
- journal article
- research article
- Published by SAGE Publications in Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery
- Vol. 5 (6), 424-429
- https://doi.org/10.1177/155698451000500608
Abstract
Objective Heparinization is thought to be mandatory to avoid thromboembolic complications during venoarterial extracorporeal membrane oxygenation (VA-ECMO). However, bleeding complications are common. We report our experience of VA-ECMO without systemic anticoagulation. Methods A prospectively assembled database describing all ECMO cases from 2000 to 2008 was analyzed. A heparin coated circuit (Medtronic, Inc., Minneapolis, MN USA) and membrane oxygenator (Quadrox D Bioline oxygenator; MAQUET, Rastatt, Germany) were used in all cases. After the initiation of VA-ECMO support, all coagulation parameters were corrected. No further systemic maintenance anticoagulant was given, except at the time of weaning. Results Thirty-two patients received VA-ECMO support; 20 patients (62.5%) were males with a median age of 52.5 years (interquartile range, 40.4–61.1 years). Central and peripheral cannulations were 53% and 47%, respectively. Etiologies of cardiogenic shock were postcardiotomy (75%, n = 24) and as a support to cardiopulmonary resuscitation in 25% of cases (n = 8). Thirty-day mortality was 43.8%. Median duration of ECMO support was 46.3 hours (interquartile range, 26.8–87.8 hours). The median number of packed red blood cell transfusions was 18 ± 25. Complications include five patients (16%) with limb ischemia requiring intervention, 15 patients (46.9%) had acute renal failure, two patients had deep vein thrombosis, and two patients had intracardiac clots detected on echocardiograms. No patient had a cerebrovascular event. Incidence of membrane oxygenator failure was low, requiring replacement in three patients; no adverse event occurred during replacement. Fourteen patients (43.8%) were re-explored for bleeding. Fourteen patients (44%) were discharged home and were long-term survivors. Conclusions VA-ECMO support without systemic anticoagulation may reduce bleeding complications and transfusion requirement, without increasing the risk of thromboembolism.Keywords
This publication has 15 references indexed in Scilit:
- Combined use of extracorporeal membrane oxygenation and activated protein C for severe acute respiratory distress syndrome and septic shockThe Journal of Thoracic and Cardiovascular Surgery, 2009
- Extracorporeal Membrane OxygenationEmergency Medicine Clinics of North America, 2008
- Venoarterial extracorporeal membrane oxygenation for treatment of cardiogenic shock: Clinical experiences in 45 adult patientsThe Journal of Thoracic and Cardiovascular Surgery, 2008
- Extracorporeal Membrane Oxygenation With a Poly-Methylpentene Oxygenator (Quadrox D). The Experience of a Single Italian Centre in Adult Patients With Refractory Cardiogenic ShockAsaio Journal, 2008
- Five-Year results of 219 consecutive patients treated with extracorporeal membrane oxygenation for refractory postoperative cardiogenic shockThe Annals of Thoracic Surgery, 2004
- Clinical experience with 202 adults receiving extracorporeal membrane oxygenation for cardiac failure: Survival at five yearsThe Journal of Thoracic and Cardiovascular Surgery, 2001
- Extracorporeal Life SupportPublished by American Medical Association (AMA) ,2000
- Heparin-bonded surfaces in extracorporeal membrane oxygenation for cardiac supportThe Annals of Thoracic Surgery, 1996
- Complications of extracorporeal life support systems using heparin-bound surfaces: The risk of intracardiac clot formationThe Journal of Thoracic and Cardiovascular Surgery, 1995
- Extracorporeal Membrane Oxygenation for Adult Post Cardiotomy Cardiogenic Shock Using a Heparin Bonded SystemASAIO Journal, 1993